CytomX Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, CytomX Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 2 currently recruiting 2 completed early-phase tilt upper quartile by trial count

CytomX Therapeutics: 8 sponsored US clinical trials, 2 recruiting.

CytomX Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumor, Adult, with 2 trials.

Upper-quartile sponsor footprint

CytomX Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

First In Human Study of CX-801 in Advanced Solid Tumors

NCT06462794
RECRUITING Phase 1

First In Human Study of CX-2051 in Advanced Solid Tumors

NCT06265688
TERMINATED Phase 1

A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

NCT05387265
COMPLETED Phase 2

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

NCT04596150
TERMINATED Phase 2

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NCT03993379
COMPLETED Phase 1

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

NCT03543813
TERMINATED Phase 1

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

NCT03149549
TERMINATED Phase 1

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

NCT03013491

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2

Therapeutic Areas

Solid Tumor, Adult 2

What is open in the CytomX Therapeutics pipeline

2 recruiting of 8 indexed (25% open); 2 completed (25%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Solid Tumor, Adult (2 trials), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

CytomX Therapeutics: open-pipeline peers nationwide

Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

CytomX Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%10%20%30%40% Total trials Recruiting share CytomX TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Abdul Latif Jameel Poverty Action LabAccutar BiotechnologyAdrienne G. WaksAdvocate Hospital System
CytomX Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

CytomX Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this CytomX Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of CytomX Therapeutics or any single study.

  • 2 of CytomX Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Solid Tumor, Adult is the condition CytomX Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumor, Adult trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

CytomX Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.